The filing discloses the approval of an amendment to the company's equity incentive plan, which is a compensatory arrangement rather than a change in management personnel.

Results of Operations and Financial Condition. On August 11, 2026, CalciMedica, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liab…

Director — Evgeny Zaytsev, M.D., Ph.D.: Dr. Evgeny Zaytsev was appointed as a new director, expanding the board size from seven to eight directors.

Unregistered Sales of Securities. To the extent required by

Entry into a Material Definitive Agreement First Amendment to Loan and Security Agreement On June 23, 2026 (the “Effective Date”), CalciMedica, Inc. (the “Company”) entered into the First Amendment to Loan Documents (the “Loan First Amendment”) to amend that certain Loan and Security Agreement and that certain Supplement to the Loan and Security Agreement each dated as of February 28, 2025 (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P. (the “Lender”) and Aven…

Other Events Company Update On June 24, 2026, the Company announced that it intends to use the proceeds of the Private Placement to advance a focused pulmonary hypertension (“PH”) strategy built on its CRAC channel inhibition platform. The Company plans to conduct a capital-efficient Phase 1b proof-of-concept study evaluating Auxora ™ , its intravenous CRAC channel inhibitor, in patients with pulmonary arterial hypertension (“PAH”), with data anticipated mid-2027. This study is intended to ge…

Regulation FD Disclosure On June 24, 2026, the Company issued a press release announcing an update on its interactions with the U.S. Food and Drug Administration (“FDA”). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. On June 24, 2026, the Company issued a press release announcing that it has entered into the Purchase Agreement and provided other business updates. A copy of the press release is attached as Ex…

Entry into a Material Definitive Agreement On June 23, 2026, CalciMedica, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain new and existing institutional and accredited investors named therein (each, an “Investor” and collectively, the “Investors”), for the private placement (the “Private Placement”) of an aggregate of 18,673,429 units (the “Units”), each Unit comprised of (i) (A) one share of the Company’s common stock, par value $0.00…

Unregistered Sales of Equity Securities The disclosures set forth in

Results of Operations and Financial Condition. On May 12, 2026, CalciMedica, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabil…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Market Value of Listed Securities On March 13, 2026, CalciMedica, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of listed securities (the “MVLS Requirement”) for the Company’s common stock had been below the minimum MVLS Requirement of $35,000,000 f…

Results of Operations and Financial Condition. On March 3, 2026, CalciMedica, Inc. issued a press release announcing its financial results for the years ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities…

Other Events. On January 28, 2026, the Company announced the Trial Discontinuation. During a prescheduled interim data review, the IDMC identified a safety concern that, in its view, warrants reevaluation of the study design, particularly with respect to patient enrollment criteria. There were no deaths in the trial that were assessed by investigators or the Company as being related to study drug (either Auxora or placebo). In addition, no serious adverse events met the criteria for expedited…

Other Events. On January 28, 2026, CalciMedica, Inc. (the “Company”) announced the discontinuation of its Phase 2 KOURAGE clinical trial following a recommendation from the trial’s Independent Data Monitoring Committee. In connection with the discontinuation of the KOURAGE trial and the resulting reduction in planned operating expenses, the Company is updating its financial guidance. The Company now expects that its existing cash, cash equivalents, and short-term investments will be sufficien…

Results of Operations and Financial Condition. On November 12, 2025 CalciMedica, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to th…

Other Events. On November 6, 2025, CalciMedica, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “SEC”) to increase the maximum aggregate offering price of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) issuable under the Company’s at-the-market offering agreement (the “Offering Agreement”) with H.C. Wainwright & Co., dated August 11, 2023, from $4,450,000 to $9,700,000…

Results of Operations and Financial Condition. On August 12, 2025 CalciMedica, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabi…

Changes in Registrant’s Certifying Accountant. On June 3, 2025, CalciMedica, Inc., (the “Company”) was notified that Moss Adams LLP (“Moss Adams”), the Company’s independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025. The combined audit practices operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the notification of the merger, Moss Adams has resigned as the auditors of the Company and the Audit Committee of the Company’s Board…

Results of Operations and Financial Condition. On May 14, 2025 CalciMedica, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabili…

Results of Operations and Financial Condition. On March 27, 2025 CalciMedica, Inc. issued a press release announcing its financial results for the fiscal year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabi…

Entry into a Material Definitive Agreement. Loan Agreement On February 28, 2025 (the “Closing Date”), CalciMedica, Inc. (the “Company”) entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P. (the “Lender”) and Avenue Capital Management II, L.P., as administrative agent and collateral agent, for growth capital loans in an aggregate principal amount of up to $32,500,000 (th…

Unregistered Sales of Equity Securities. To the extent required by

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Other Events. On March 4, 2025, the Company announced new data from a post-hoc analysis of the previously completed CARDEA trial, the Company’s Phase 2 trial evaluating Auxora for the treatment of severe COVID-19 pneumonia. The study included a subset of 38 patients who enrolled with Acute Kidney Injury (“AKI”), defined as an estimated glomerular filtration rate (“eGFR”) ≤ 60 ml/min/1.73 m², in addition to moderate or severe respiratory failure, which was an inclusion criterion. Within this s…

Director and Chair of the audit committee — Eric Bjerkholt: Eric Bjerkholt resigned from the board and as Chair of the audit committee with a successor appointed.